Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
The New England Journal of Medicine
|
June 7, 2005
Treatment of brain tumors
Robert D Aiken
Seminars in Oncology
|
June 14, 2006
Neurologic complications of head and neck cancers
Robert D Aiken
Seminars in Oncology
|
September 1, 2014
Primary brain tumors: introduction
Robert D Aiken, Richard W Byrne
Brain Pathology (Zurich, Switzerland)
|
August 15, 2017
A 54-Year-Old Male with Multiple Intracranial and Extracranial Masses
Diana Murro Lin, Aidnag Z Diaz, Robert D Aiken, et al.
Journal of Neuro-Oncology
|
August 31, 2012
Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme
Kenneth F Grossmann, Howard Colman, Wallace A Akerley, et al.
Human Vaccines & Immunotherapeutics
|
September 12, 2025
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival
Daniela A Bota, David E Piccioni, Christopher M Duma, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
December 14, 2022
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
Daniela A Bota, Thomas H Taylor, David E Piccioni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 20, 2019
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
Patrick Y Wen, David A Reardon, Terri S Armstrong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 24, 2017
First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors
Mark N Stein, Joseph R Bertino, Howard L Kaufman, et al.
Journal for Immunotherapy of Cancer
|
May 24, 2019
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
Mark N Stein, Jyoti Malhotra, Rohinton S Tarapore, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
The New England Journal of Medicine
|
June 7, 2005
Treatment of brain tumors
Robert D Aiken
Seminars in Oncology
|
June 14, 2006
Neurologic complications of head and neck cancers
Robert D Aiken
Seminars in Oncology
|
September 1, 2014
Primary brain tumors: introduction
Robert D Aiken, Richard W Byrne
Brain Pathology (Zurich, Switzerland)
|
August 15, 2017
A 54-Year-Old Male with Multiple Intracranial and Extracranial Masses
Diana Murro Lin, Aidnag Z Diaz, Robert D Aiken, et al.
Journal of Neuro-Oncology
|
August 31, 2012
Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme
Kenneth F Grossmann, Howard Colman, Wallace A Akerley, et al.
Human Vaccines & Immunotherapeutics
|
September 12, 2025
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival
Daniela A Bota, David E Piccioni, Christopher M Duma, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
December 14, 2022
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
Daniela A Bota, Thomas H Taylor, David E Piccioni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 20, 2019
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
Patrick Y Wen, David A Reardon, Terri S Armstrong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 24, 2017
First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors
Mark N Stein, Joseph R Bertino, Howard L Kaufman, et al.
Journal for Immunotherapy of Cancer
|
May 24, 2019
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
Mark N Stein, Jyoti Malhotra, Rohinton S Tarapore, et al.
Page
of 2